Registered title, quoted from ClinicalTrials.gov
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Xuzhou Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07034755, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Diagnosis: Multiple myeloma confirmed by physical examination, pathological examination, laboratory tests, and imaging studies
Inclusion criterion 3
Performance status: Karnofsky Performance Status (KPS) >50%
Inclusion criterion 9
ALT and AST < 3 times the upper limit of normal
Inclusion criterion 7
Bilirubin < 2.0 mg/dl
Inclusion criterion 8
Infectious diseases(e.g., HIV, active tuberculosis)
Exclusion criterion 2
Pregnancy or lactation, or women planning pregnancy within the next 6 months
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07034755, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age: 18-70 years old
- Expected survival: >12 weeks
- Diagnosis: Multiple myeloma confirmed by physical examination, pathological examination, laboratory tests, and imaging studies
- Post-chemotherapy status:
- Patients who achieved partial response (PR) or better but failed to reach complete response (CR) after four cycles of first-line chemotherapy Patients who achieved CR after four cycles of first-line chemotherapy but have high-risk factors
- Liver function:
- ALT and AST < 3 times the upper limit of normal
- Bilirubin < 2.0 mg/dl
- Performance status: Karnofsky Performance Status (KPS) >50%
- Organ function: No severe liver, kidney, or heart diseases
- Stem cell transplantation: Eligible for stem cell transplantation
- Venous access: Able to undergo venous blood sampling without contraindications to leukapheresis
- Informed consent: Capable of understanding and voluntarily signing a written informed consent form
Exclusion Criteria:
- Pregnancy or lactation, or women planning pregnancy within the next 6 months
- Infectious diseases(e.g., HIV, active tuberculosis)
- Active hepatitis B or C infection
- Feasibility assessment showing lymphocyte-targeted transfection rate <10% or insufficient expansion (<5-fold) under CD3/CD28 co-stimulation
- Abnormal vital signs or inability to cooperate with examinations
- Psychiatric/psychological disorders precluding treatment compliance or efficacy evaluation
- Severe allergic constitution or history of severe allergies, especially to IL-2
- Systemic or localized severe infection requiring anti-infective therapy
- Severe autoimmune diseases
- Other conditions deemed unsuitable for inclusion by the investigator
Quoted from ClinicalTrials.gov, NCT07034755, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07034755, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.